• Mayr-Melnhof Karton sees direct-to-patient drug delivery expanding pharmaceutical packaging’s role beyond logistics to patient experience.
• A 2025 industry survey found 73% of pharmaceutical executives’ companies operated direct-to-patient programs or planned launches in 2026.
• Half of respondents expected direct distribution models could become standard within five years.
• The shift increases the importance of discreet, accessible packaging, with connected technologies offering opportunities to support treatment information and temperature monitoring.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mayr-Melnhof Karton AG published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.